Suppr超能文献

靶向转录因子 Ikaros 和 Aiolos 对系统性红斑狼疮中 B 细胞激活和分化的影响。

Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus.

机构信息

Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Rheumatology Department, Barts Health NHS Trust, London, UK.

出版信息

Lupus Sci Med. 2021 Mar;8(1). doi: 10.1136/lupus-2020-000445.

Abstract

OBJECTIVE

To evaluate the effects of targeting Ikaros and Aiolos by cereblon modulator iberdomide on the activation and differentiation of B-cells from patients with systemic lupus erythematosus (SLE).

METHODS

CD19 B-cells isolated from the peripheral blood of patients with SLE (n=41) were cultured with TLR7 ligand resiquimod ±IFNα together with iberdomide or control from day 0 (n=16). Additionally, in vitro B-cell differentiation was induced by stimulation with IL-2/IL-10/IL-15/CD40L/resiquimod with iberdomide or control, given at day 0 or at day 4. At day 5, immunoglobulins were measured by ELISA and cells analysed by flow cytometry. RNA-Seq was performed on fluorescence-activated cell-sorted CD27IgD naïve-B-cells and CD20CD27CD38 plasmablasts to investigate the transcriptional consequences of iberdomide.

RESULTS

Iberdomide significantly inhibited the TLR7 and IFNα-mediated production of immunoglobulins from SLE B-cells and the production of antinuclear antibodies as well as significantly reducing the number of CD27CD38 plasmablasts (0.3±0.18, vehicle 1.01±0.56, p=0.011) and CD138 plasma cells (0.12±0.06, vehicle 0.28±0.02, p=0.03). Additionally, treatment with iberdomide from day 0 significantly inhibited the differentiation of SLE B-cells into plasmablasts (6.4±13.5 vs vehicle 34.9±20.1, p=0.013) and antibody production. When given at later stages of differentiation, iberdomide did not affect the numbers of plasmablasts or the production of antibodies; however, it induced a significant modulation of gene expression involving and transcriptional programmes in both naïve B-cells and plasmablasts (400 and 461 differentially modulated genes, respectively, false discovery rate<0.05).

CONCLUSION

These results demonstrate the relevance of Ikaros and Aiolos as therapeutic targets in SLE due to their ability to modulate B cell activation and differentiation downstream of TLR7.

摘要

目的

评估靶向 cereblon 调节剂来那度胺对系统性红斑狼疮(SLE)患者 B 细胞激活和分化的影响。

方法

从 SLE 患者的外周血中分离出 CD19+B 细胞(n=41),从第 0 天(n=16)开始用 TLR7 配体 resiquimod+IFNα与来那度胺或对照物共培养。此外,通过用 IL-2/IL-10/IL-15/CD40L/resiquimod 在第 0 天或第 4 天给予来那度胺或对照物,诱导体外 B 细胞分化。在第 5 天,通过 ELISA 测量免疫球蛋白,通过流式细胞术分析细胞。对荧光激活细胞分选的 CD27IgD 幼稚-B 细胞和 CD20CD27CD38 浆母细胞进行 RNA-Seq,以研究来那度胺的转录后果。

结果

来那度胺显著抑制了 SLE B 细胞 TLR7 和 IFNα 介导的免疫球蛋白产生以及抗核抗体的产生,并显著减少了 CD27CD38 浆母细胞(0.3±0.18,载体 1.01±0.56,p=0.011)和 CD138 浆细胞(0.12±0.06,载体 0.28±0.02,p=0.03)的数量。此外,从第 0 天开始用来那度胺治疗可显著抑制 SLE B 细胞向浆母细胞(6.4±13.5 对载体 34.9±20.1,p=0.013)和抗体产生的分化。当在分化的后期给予来那度胺时,它不会影响浆母细胞的数量或抗体的产生,但它会诱导在幼稚 B 细胞和浆母细胞中涉及 和 转录程序的显著基因表达调节(分别有 400 和 461 个差异调节基因,错误发现率<0.05)。

结论

这些结果表明,由于 Ikaros 和 Aiolos 能够调节 TLR7 下游的 B 细胞激活和分化,因此它们是 SLE 治疗的潜在靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7768/7970264/dceed140813c/lupus-2020-000445f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验